Literature DB >> 6167863

Comparative antiviral efficiency of leukocyte and bacterially produced human alpha-interferon in rhesus monkeys.

H Schellekens, A de Reus, R Bolhuis, M Fountoulakis, C Schein, J Ecsödi, S Nagata, C Weissmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6167863     DOI： 10.1038/292775a0

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  8 in total

1.  Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro.

Authors:  F G Hayden; A N Schlepushkin; N L Pushkarskaya
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

2.  Structure and expression in Escherichia coli of a cloned rat interferon-alpha gene.

Authors:  R Dijkema; P Pouwels; A de Reus; H Schellekens
Journal:  Nucleic Acids Res       Date:  1984-01-25       Impact factor: 16.971

Review 3.  Preclinical safety testing of species-specific proteins produced with recombinant DNA-techniques. An attempt to transfer current experience into future testing strategies.

Authors:  K Teelmann; C Hohbach; H Lehmann
Journal:  Arch Toxicol       Date:  1986-12       Impact factor: 5.153

Review 4.  The immunologic aspects of poxvirus oncolytic therapy.

Authors:  Andrea Worschech; D Haddad; D F Stroncek; E Wang; Francesco M Marincola; Aladar A Szalay
Journal:  Cancer Immunol Immunother       Date:  2009-03-06       Impact factor: 6.968

Review 5.  Poxvirus pathogenesis.

Authors:  R M Buller; G J Palumbo
Journal:  Microbiol Rev       Date:  1991-03

6.  Constitutive, long-term production of human interferons by hamster cells containing multiple copies of a cloned interferon gene.

Authors:  J Haynes; C Weissmann
Journal:  Nucleic Acids Res       Date:  1983-02-11       Impact factor: 16.971

7.  Antiviral effects of bacteria-derived human leukocyte interferons against encephalomyocarditis virus infection of squirrel monkeys. Brief report.

Authors:  N Stebbing; P K Weck; J T Fenno; D A Estell; E Rinderknecht
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

Review 8.  Repurposing approved drugs on the pathway to novel therapies.

Authors:  Catherine H Schein
Journal:  Med Res Rev       Date:  2019-08-20       Impact factor: 12.944
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.